Dynamics of molecular response in AML patients with NPM1 and FLT3 mutations undergoing allogeneic stem cell transplant.

about

Dynamics of molecular response in AML patients with NPM1 and FLT3 mutations undergoing allogeneic stem cell transplant.

Item

http://www.wikidata.org/entity/Q48328410

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Dynamics of molecular response ...... logeneic stem cell transplant.

@en

Dynamics of molecular response ...... logeneic stem cell transplant.

@nl

type

Item

label

Dynamics of molecular response ...... logeneic stem cell transplant.

@en

Dynamics of molecular response ...... logeneic stem cell transplant.

@nl

prefLabel

Dynamics of molecular response ...... logeneic stem cell transplant.

@en

Dynamics of molecular response ...... logeneic stem cell transplant.

@nl

P1476

Dynamics of molecular response ...... logeneic stem cell transplant.

@en

P2093

B Haffar

http://www.w3.org/2001/XMLSchema#string

J El-Cheikh

http://www.w3.org/2001/XMLSchema#string

R Mahfouz

http://www.w3.org/2001/XMLSchema#string

R Salem

http://www.w3.org/2001/XMLSchema#string

P2860

Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.

The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

Assessment of Minimal Residual Disease in Standard-Risk AML.

Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib

Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia.

High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials.

Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.

AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features.

P2888

bmt.2017.82

P304

1187-1190

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BMT.2017.82

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ali Bazarbachi

Radwan Massoud

P577

2017-06-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28581462

http://www.w3.org/2001/XMLSchema#string